Zhengye Biotechnology Holding L (ZYBT): Financials
Fiscal year ended December 31, 2025
Income statement, cash flow and balance sheet figures for Zhengye Biotechnology Holding L (ZYBT), read directly from the XBRL data the company files with the SEC. Over the most recent fiscal year the company reported $16.6M of revenue, down 34.8% year over year. Net loss was $10.0M. Free cash flow was $1.8M. Gross margin stood at 20.5%.
Against the current share price, ZYBT trades at 4.5 times trailing revenue.
4 fiscal years of history are available, back to 2022.
Frequently asked questions
How much revenue does ZYBT make?
Zhengye Biotechnology Holding L reported $16.6M of revenue over the most recent fiscal year, for the period ended December 31, 2025. That is down 34.8% from the same period a year earlier.
Is ZYBT profitable?
Zhengye Biotechnology Holding L was unprofitable over the most recent fiscal year, with a net loss of $10.0M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.